289 related articles for article (PubMed ID: 26720415)
21. Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis.
Reid DW; Campos RK; Child JR; Zheng T; Chan KWK; Bradrick SS; Vasudevan SG; Garcia-Blanco MA; Nicchitta CV
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321322
[TBL] [Abstract][Full Text] [Related]
22. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
23. Melatonin Inhibits Dengue Virus Infection via the Sirtuin 1-Mediated Interferon Pathway.
Morchang A; Malakar S; Poonudom K; Noisakran S; Yenchitsomanus PT; Limjindaporn T
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920458
[TBL] [Abstract][Full Text] [Related]
24. A MicroRNA Screen Identifies the Wnt Signaling Pathway as a Regulator of the Interferon Response during Flavivirus Infection.
Smith JL; Jeng S; McWeeney SK; Hirsch AJ
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148804
[TBL] [Abstract][Full Text] [Related]
25. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
Sun J; Li M; Wang Y; Hao P; Jin X
Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.
Grifoni A; Angelo M; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Botten J; Boyson J; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148797
[TBL] [Abstract][Full Text] [Related]
27. Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue.
Upasani V; Scagnolari C; Frasca F; Smith N; Bondet V; Vanderlinden A; Lay S; Auerswald H; Heng S; Laurent D; Ly S; Duong V; Antonelli G; Dussart P; Duffy D; Cantaert T
Front Immunol; 2020; 11():605087. PubMed ID: 33391269
[TBL] [Abstract][Full Text] [Related]
28. [Research progress in the structure and function of dengue virus non-structural 1 protein].
Chen Y; Ren RW; Liu JW
Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
[TBL] [Abstract][Full Text] [Related]
29. Mouse models for dengue vaccines and antivirals.
Plummer EM; Shresta S
J Immunol Methods; 2014 Aug; 410():34-8. PubMed ID: 24440090
[TBL] [Abstract][Full Text] [Related]
30. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
31. Induction of anti-viral genes mediated by humoral factors upon stimulation with Lactococcus lactis strain plasma results in repression of dengue virus replication in vitro.
Tsuji R; Yamamoto N; Yamada S; Fujii T; Yamamoto N; Kanauchi O
Antiviral Res; 2018 Dec; 160():101-108. PubMed ID: 30393011
[TBL] [Abstract][Full Text] [Related]
32. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
[TBL] [Abstract][Full Text] [Related]
33. Dengue virus infection induces interferon-lambda1 to facilitate cell migration.
Hsu YL; Wang MY; Ho LJ; Lai JH
Sci Rep; 2016 Jul; 6():24530. PubMed ID: 27456172
[TBL] [Abstract][Full Text] [Related]
34. DDX50 inhibits the replication of dengue virus 2 by upregulating IFN-β production.
Han P; Ye W; Lv X; Ma H; Weng D; Dong Y; Cheng L; Chen H; Zhang L; Xu Z; Lei Y; Zhang F
Arch Virol; 2017 Jun; 162(6):1487-1494. PubMed ID: 28181036
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in dengue vaccine development.
Wei J; Chen H; An J
Virol Sin; 2014 Dec; 29(6):353-63. PubMed ID: 25547681
[TBL] [Abstract][Full Text] [Related]
36. Live attenuated vaccine: the first clinically approved dengue vaccine?
Fink K; Shi PY
Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
[TBL] [Abstract][Full Text] [Related]
37. Innate immunity to dengue virus infection and subversion of antiviral responses.
Green AM; Beatty PR; Hadjilaou A; Harris E
J Mol Biol; 2014 Mar; 426(6):1148-60. PubMed ID: 24316047
[TBL] [Abstract][Full Text] [Related]
38. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility and initial immune response of Tupaia belangeri cells to dengue virus infection.
Kayesh MEH; Kitab B; Sanada T; Hayasaka D; Morita K; Kohara M; Tsukiyama-Kohara K
Infect Genet Evol; 2017 Jul; 51():203-210. PubMed ID: 28392469
[TBL] [Abstract][Full Text] [Related]
40. IFN-γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent manner.
Fagundes CT; Costa VV; Cisalpino D; Amaral FA; Souza PR; Souza RS; Ryffel B; Vieira LQ; Silva TA; Atrasheuskaya A; Ignatyev G; Sousa LP; Souza DG; Teixeira MM
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1449. PubMed ID: 22206036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
